Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Impatient patients turn to online 'buyers club' for new drugs

    Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club. While regulators warn of the risk of buying drugs online, the Amsterdam-based Social Medwork sees its network of trusted suppliers as filling a gap in the market for the latest drugs against diseases such as cancer, migraine and multiple sclerosis.

    03 October 2018 | Reuters
  • Fears over HIV drugs in event of ‘no deal’ Brexit

    Healthcare advocates highlight concerns over slower access to the newest HIV drugs when the UK leaves the European Union next year

    02 October 2018 | Gay Star News
  • What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

    There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large drug and biotech companies have done so in recent years, and this is what is being seen at Gilead Sciences Inc.

    25 September 2018 | 24/7 Wall St.
  • Gilead to launch generic versions of its hepatitis drugs

    Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

    25 September 2018 | Reuters
  • Brazil court strips Gilead hepatitis drug patent, politician says

    A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

    25 September 2018 | Reuters
  • European advisory group backs Merck's HIV meds Delstrigo and Pifeltro

    The European Medicines Agency's advisory group CHMP adopts a positive opinion backing approval for Merck's (NYSE:MRK) DELSTRIGO (doravirine, lamivudine and tenofovir disoproxil fumarate) and PIFELTRO (doravirine) for the treatment of adults with chronic HIV-1 infection.

    24 September 2018 | Seeking Alpha
  • PrEP drug patent overturned in UK - NAT respond

    The High Court has today overturned Gilead's patent extension on Truvada, the HIV drug also used in PrEP.

    18 September 2018 | National AIDS Trust
  • A Crazy, Murky System for Pricing HIV Drugs

    A new gold-standard triple therapy for H.I.V. has just made its debut in Africa. It costs $75 a year. In the United States, many people with H.I.V. take an almost identical therapy. It costs $39,000 a year. The United States is infamous for its high cost of health care — and HIV medicines are a big part of that.

    18 September 2018 | New York Times
  • EPO Upholds Gilead Patent On Hep C Medicines, But In Amended Form

    The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained in an amended form. Civil society involved in the case expressed dismay over the outcome and its potential effect on European drug prices.

    16 September 2018 | Intellectual Property Watch
  • Groups Call for End to Gilead’s Unwarranted Hepatitis C Drug Monopoly in Europe

    This week in Munich, the European Patent Office (EPO) will hear a legal challenge filed by groups in 17 countries against an unmerited patent that allows US-based pharmaceutical corporation Gilead Sciences to charge exorbitant prices in Europe for the key hepatitis C drug sofosbuvir.

    11 September 2018 | MSF press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.